Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration
- PMID: 6152055
- DOI: 10.1007/BF00431449
Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration
Abstract
Six fasting male subjects (20-32 years of age) received an oral tablet and an IV 1.0-mg dose of alprazolam in a crossover-design study. Alprazolam plasma concentration in multiple samples during 36 h after dosing was determined by electron-capture gas-liquid chromatography. Psychomotor performance tests, digit-symbol substitution (DSS), and perceptual speed (PS) were administered at 0, 1.25, 2.25, 5.0, and 12.5 h. Sedation was assessed by the subjects and by an observer using the Stanford Sleepiness Scale and a Nurse Rating Sedation Scale (NRSS), respectively. Mean kinetic parameters after IV and oral alprazolam were as follows: volume of distribution (Vd) 0.72 and 0.84 l/kg; elimination half-life (t1/2) 11.7 and 11.8 h; clearance (Cl) 0.74 and 0.89 ml/min/kg. There were no significant differences between IV and oral alprazolam in Vd, t1/2, or area under the curve. The mean fraction absorbed after oral administration was 0.92. Performance on PS and DSS tests was impaired at 1.25 and 2.5 h, but had returned to baseline at 5.0 h for both treatments. Onset of sedation was rapid after IV administration and the average time of peak sedation was 0.48 h. Sedation scores were significantly lower during hour 1 after oral administration than after IV, but were not significantly different at later times. Alprazolam is fully available after oral administration and kinetic parameters are not affected by route of administration. With the exception of rapidity of onset, the pharmacodynamic profiles of IV and oral alprazolam are very similar after a 1.0-mg dose.
Similar articles
-
Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers.J Clin Pharmacol. 2005 May;45(5):529-37. doi: 10.1177/0091270004269105. J Clin Pharmacol. 2005. PMID: 15831776 Clinical Trial.
-
Pharmacokinetics and psychomotor performance of alprazolam: concentration-effect relationship.J Clin Pharmacol. 1997 Apr;37(4):321-9. doi: 10.1002/j.1552-4604.1997.tb04309.x. J Clin Pharmacol. 1997. PMID: 9115058 Clinical Trial.
-
Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics.Clin Pharmacol Ther. 1984 Nov;36(5):683-90. doi: 10.1038/clpt.1984.240. Clin Pharmacol Ther. 1984. PMID: 6149030
-
Pharmacokinetics of the newer benzodiazepines.Clin Pharmacokinet. 1989 Jun;16(6):337-64. doi: 10.2165/00003088-198916060-00002. Clin Pharmacokinet. 1989. PMID: 2567646 Review.
-
Clinical pharmacokinetics of alprazolam. Therapeutic implications.Clin Pharmacokinet. 1993 Jun;24(6):453-71. doi: 10.2165/00003088-199324060-00003. Clin Pharmacokinet. 1993. PMID: 8513649 Review.
Cited by
-
Extent and variability of the first-pass elimination of adinazolam mesylate in healthy male volunteers.Pharm Res. 1991 Feb;8(2):162-7. doi: 10.1023/a:1015875516834. Pharm Res. 1991. PMID: 2023863
-
Lack of effect of influenza vaccine on the pharmacokinetics of antipyrine, alprazolam, paracetamol (acetaminophen) and lorazepam.Clin Pharmacokinet. 1989 Mar;16(3):180-5. doi: 10.2165/00003088-198916030-00004. Clin Pharmacokinet. 1989. PMID: 2721087
-
Lack of interaction between disulfiram and alprazolam in alcoholic patients.Eur J Clin Pharmacol. 1990;38(2):157-60. doi: 10.1007/BF00265976. Eur J Clin Pharmacol. 1990. PMID: 2338112
-
Pharmacokinetic interactions with rifampicin : clinical relevance.Clin Pharmacokinet. 2003;42(9):819-50. doi: 10.2165/00003088-200342090-00003. Clin Pharmacokinet. 2003. PMID: 12882588 Review.
-
Alprazolam-related deaths in Scotland, 2004-2020.J Psychopharmacol. 2022 Sep;36(9):1020-1035. doi: 10.1177/02698811221104065. Epub 2022 Aug 1. J Psychopharmacol. 2022. PMID: 35912873 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources